Ignyta (RXDX) Will Present RXDX-106 Preclinical Data at Upcoming Conference
Tweet Send to a Friend
Ignyta, Inc. (Nasdaq: RXDX) announced its first disclosed preclinical data on RXDX-106—its potent, selective, type II pseudo-irreversible inhibitor of TYRO3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
